📊 PALI Key Takeaways
Is Palisade Bio, Inc.. (PALI) a Good Investment?
Palisade Bio is a pre-revenue biotech with exceptionally strong financial health: $132.6M cash, minimal debt, and a 34+ year cash runway at current burn rates. However, zero revenue and lack of visible commercialization pathway limit upside assessment; the 97.1% YoY improvement in EPS losses suggests operational discipline, but fundamental progress remains elusive.
Palisade Bio, Inc.. Key Strengths (PALI)
- Exceptional liquidity position with $132.6M cash (99.5% of total assets) and 23.71x current ratio
- Minimal debt burden ($87K long-term) and fortress balance sheet with $127.4M stockholders' equity
- Significant 97.1% YoY improvement in diluted EPS losses, indicating operational efficiency gains
PALI Stock Risks: Palisade Bio, Inc.. Investment Risks
- Zero revenue with no evidence of commercial product viability or market acceptance
- Negative operating cash flow of $3.9M annually indicates persistent capital burn without offsetting revenue
- Pre-revenue biotech status with unclear clinical pipeline, regulatory approval timeline, and path to profitability
Key Metrics to Watch
- Revenue generation timeline and first commercial product launch milestones
- Operating cash burn rate trajectory and remaining cash runway sustainability
- Clinical development pipeline progression and regulatory approval status
Palisade Bio, Inc.. (PALI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 23.71x current ratio provides a solid financial cushion.
PALI Profit Margin, ROE & Profitability Analysis
PALI vs Healthcare Sector: How Palisade Bio, Inc.. Compares
How Palisade Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Palisade Bio, Inc.. Stock Overvalued? PALI Valuation Analysis 2026
Based on fundamental analysis, Palisade Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Palisade Bio, Inc.. Balance Sheet: PALI Debt, Cash & Liquidity
PALI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Palisade Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.19 indicates the company is currently unprofitable.
PALI Revenue Growth, EPS Growth & YoY Performance
PALI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$3.5M | $-2.32 |
| Q2 2024 | N/A | -$3.4M | $-3.32 |
| Q1 2024 | N/A | -$2.3M | $-4.59 |
| Q3 2023 | N/A | -$3.6M | $-0.49 |
| Q2 2023 | N/A | -$2.3M | $-0.53 |
| Q1 2023 | N/A | -$2.3M | $-0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Palisade Bio, Inc.. Dividends, Buybacks & Capital Allocation
PALI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Palisade Bio, Inc.. (CIK: 0001357459)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PALI
What is the AI rating for PALI?
Palisade Bio, Inc.. (PALI) has an AI grade of B with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PALI's key strengths?
Claude: Exceptional liquidity position with $132.6M cash (99.5% of total assets) and 23.71x current ratio. Minimal debt burden ($87K long-term) and fortress balance sheet with $127.4M stockholders' equity.
What are the risks of investing in PALI?
Claude: Zero revenue with no evidence of commercial product viability or market acceptance. Negative operating cash flow of $3.9M annually indicates persistent capital burn without offsetting revenue.
What is PALI's revenue and growth?
Palisade Bio, Inc.. reported revenue of $0.0.
Does PALI pay dividends?
Palisade Bio, Inc.. does not currently pay dividends.
Where can I find PALI SEC filings?
Official SEC filings for Palisade Bio, Inc.. (CIK: 0001357459) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PALI's EPS?
Palisade Bio, Inc.. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PALI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Palisade Bio, Inc.. has a B grade with 55% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PALI stock overvalued or undervalued?
Valuation metrics for PALI: ROE of -7.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PALI's AI grade for 2026?
Our dual AI analysis gives Palisade Bio, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PALI's free cash flow?
Palisade Bio, Inc..'s operating cash flow is $-3.9M, with capital expenditures of $0.0.
How does PALI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -7.5% (avg: 15%), current ratio 23.71 (avg: 2).